

## REFERENCES

- Abdulkarim, B.S., Cuartero, J., Hanson, J., Deschênes, J., Lesniak, D., and Sabri, S., 2011. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **29**: 2852–2858.
- Ajani, J., 2006. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. *Cancer*, **107**: 221–231.
- AJCC Cancer Staging Manual 8th Edition, 2017. , in: *AJCC Cancer Staging Manual*. Springer, New York, pages 624–633.
- Alberts, D.S. and Garcia, D.J., 1997. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. *Drugs*, **54 Suppl 4**: 30–35.
- Alkabban, F.M. and Ferguson, T., 2022. Breast Cancer, in: *Breast Cancer*. Treasure Island (FL): Statpearls Publishing, In: Statpearls [Internet}.
- Alkabban, F.M. and Ferguson, T., 2023. Breast Cancer, in: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Ameen, M., Taylor, D.A., Williams, I.P., Wells, A.U., and Barkert, J.N., 2001. Pneumonitis complicating methotrexate therapy for pustular psoriasis. *Journal of the European Academy of Dermatology and Venereology: JEADV*, **15**: 247–249.
- Anders, C.K., Deal, A.M., Miller, C.R., Khorram, C., Meng, H., Burrows, E., et al., 2011. The prognostic contribution of clinical breast cancer subtype, age, and

race among patients with breast cancer brain metastases. *Cancer*, **117**: 1602–1611.

Baan, J., 2014. Capecitabine-induced Toxicity: An Outcome Study into Drug Safety. *Journal of Integrative Oncology*, **03**: .

Bagegni, N.A., Tao, Y., and Ademuyiwa, F.O., 2019. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. *PLOS ONE*, **14**: e0222358.

Bajetta, E., Di Bartolomeo, M., Mariani, L., Cassata, A., Artale, S., Frustaci, S., et al., 2004. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. *Cancer*, **100**: 279–287.

Batista, N., Perez-Manga, G., Constenla, M., Ruiz, A., Carabantes, F., Castellanos, J., et al., 2004. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. *British Journal of Cancer*, **90**: 1740–1746.

Beaubrun-Renard, M.M., Veronique-Baudin, J., Macni, J., Ulric-Gervaise, S., Almont, T., Aline-Fardin, A., et al., 2022. Overall survival of triple negative breast cancer in French Caribbean women. *PLoS ONE*, **17**: e0271966.

Berrada, N., Delaloge, S., and André, F., 2010. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **21 Suppl 7**: vii30-35.

- Blancato, J., Singh, B., Liu, A., Liao, D.J., and Dickson, R.B., 2004. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. *British Journal of Cancer*, **90**: 1612–1619.
- Brown, D.C. and Gatter, K.C., 2002. Ki67 protein: the immaculate deception? *Histopathology*, **40**: 2–11.
- Buisseret, L., Specht, J., Dees, E.C., Berger, R., Gupta, S., Geva, R., et al., 2015. A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC). *In Cancer Research*, **75**: S1-09-S1-09.
- Cain, E.H., Saha, A., Harowicz, M.R., Marks, J.R., Marcom, P.K., and Mazurowski, M.A., 2019. Multivariate Machine Learning Models for Prediction of Pathologic Response to Neoadjuvant Therapy in Breast Cancer using MRI features: A Study Using an Independent Validation Set. *Breast cancer research and treatment*, **173**: 455–463.
- Cardoso, F., Senkus-Konefka, E., Fallowfield, L., Costa, A., Castiglione, M., and ESMO Guidelines Working Group, 2010. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **21 Suppl 5**: v15-19.
- Cheema, P.K. and Burkes, R.L., 2013. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. *Current Oncology (Toronto, Ont.)*, **20**: e150-160.

Chen, D., Wang, Q., Dong, M., Chen, F., Huang, A., Chen, C., et al., 2023. Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution. *BMC Cancer*, **23**: 984.

Chlebowski, R.T., Col, N., Winer, E.P., Collyar, D.E., Cummings, S.R., Vogel, V.G., et al., 2002. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **20**: 3328–3343.

Clark, B.Z., Onisko, A., Assylbekova, B., Li, X., Bhargava, R., and Dabbs, D.J., 2019. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. *Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc*, **32**: 354–366.

Clark, T.G., Bradburn, M.J., Love, S.B., and Altman, D.G., 2003. Survival Analysis Part I: Basic concepts and first analyses. *British Journal of Cancer*, **89**: 232–238.

Colleoni, M., Rocca, A., Sandri, M.T., Zorzino, L., Masci, G., Nolè, F., et al., 2002. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. *Annals of Oncology*, **13**: 73–80.

Cossetti, R.J.D., Tyldesley, S.K., Speers, C.H., Zheng, Y., and Gelmon, K.A., 2015. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. *Journal of*

*Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **33**: 65–73.

Cramer, E.M. and Bock, R.D., 1966. Multivariate Analysis. *Review of Educational Research*, **36**: 604–617.

Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., et al., 2008. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *The New England Journal of Medicine*, **358**: 36–46.

Dawood, S., Broglio, K., Esteva, F.J., Yang, W., Kau, S.-W., Islam, R., et al., 2009. Survival among women with triple receptor-negative breast cancer and brain metastases. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **20**: 621–627.

Delgado, A. and Guddati, A.K., 2021. Clinical endpoints in oncology - a primer. *American Journal of Cancer Research*, **11**: 1121–1131.

Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., et al., 2007. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. *Clinical Cancer Research*, **13**: 4429–4434.

Di Leone, A., Franco, A., Zotta, F., Scardina, L., Sicignano, M., Di Guglielmo, E., et al., 2023. Local Treatment of Triple-Negative Breast Cancer: Is Mastectomy Superior to Breast-Conserving Surgery? *Journal of Personalized Medicine*, **13**: 865.

Driscoll, J.J. and Rixe, O., 2009. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. *Cancer Journal (Sudbury, Mass.)*, **15**: 401–405.

Dunton, C.J., 2002. Management of Treatment-Related Toxicity in Advanced Ovarian Cancer. *The Oncologist*, **7**: 11–19.

Eisenhauer, E.A., ten Bokkel Huinink, W.W., Swenerton, K.D., Gianni, L., Myles, J., van der Burg, M.E., et al., 1994. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **12**: 2654–2666.

Elsayed, A.G., Srivastava, R., Pacioles, T., Limjoco, T., and Tirona, M.T., 2017. Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination. *Case Reports in Oncology*, **10**: 689–693.

Eom, H.-J., Cha, J.H., Kim, H.H., Shin, H.J., Chae, E.Y., and Choi, W.J., 2021. Recurrence in Stage I and II Triple-Negative Breast Cancer: Analysis of Clinicopathologic Factors and Imaging Findings. *The Korean Society for Breast Screening*, **18**: 36–46.

Feigin, A., 2004. Evidence from biomarkers and surrogate endpoints. *NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics*, **1**: 323–330.

Foulkes, W.D., Smith, I.E., and Reis-Filho, J.S., 2010. Triple-negative breast cancer. *The New England Journal of Medicine*, **363**: 1938–1948.

Franklin, H.R., Simonetti, G.P.C., Dubbelman, A.C., Ten Bokkel Huinink, W.W., Taal, B.G., Wigbout, G., et al., 1994. Toxicity grading systems. *Annals of Oncology*, **5**: 113–117.

- Freedman, G.M., Anderson, P.R., Li, T., and Nicolaou, N., 2009. Local-Regional Recurrence of Triple Negative Breast Cancer after Breast-Conserving Surgery and Radiation. *Cancer*, **115**: 946–951.
- Ge, J., Zuo, W., Chen, Y., Shao, Z., and Yu, K., 2021. The advance of adjuvant treatment for triple-negative breast cancer. *Cancer Biology & Medicine*, **19**: 187–201.
- Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A., 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. *European Journal of Cancer (Oxford, England: 1990)*, **37**: 1590–1598.
- Gelmon, K., Eisenhauer, E., Bryce, C., Tolcher, A., Mayer, L., Tomlinson, E., et al., 1999. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **17**: 3038–3047.
- Gennari, A., Sormani, M.P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., et al., 2008. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. *Journal of the National Cancer Institute*, **100**: 14–20.
- Ghafouri, S.N., Nayeri, R.W., McAndrew, N.P., and Hurvitz, S.A., 2022. Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis. *Therapeutic Advances in Medical Oncology*, **14**: 17588359221085556.

Ghosn, M., Hajj, C., Kattan, J., Farhat, F., El Karak, F., Nasr, F., et al., 2011. Triple-negative breast cancer in Lebanon: a case series. *The Oncologist*, **16**: 1552–1556.

Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., and Harbeck, N., 2009. Triple-negative breast cancer—current status and future directions. *Annals of Oncology*, **20**: 1913–1927.

Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B., et al., 2013. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, **24**: 2206–2223.

Gupta, S., Nair, N.S., Hawaldar, R., Vanmali, V., Parmar, V., Gulia, S., et al., 2023. Abstract GS5-01: Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. *Cancer Research*, **83**: GS5-01.

Hamed, K.M., Dighriri, I.M., Baomar, A.F., Alharthy, B.T., Alenazi, F.E., Alali, G.H., et al., n.d. Overview of Methotrexate Toxicity: A Comprehensive Literature Review. *Cureus*, **14**: e29518.

Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., et al., 2002. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. *Cancer*, **94**: 25–36.



- Hermansyah, D., Rahayu, Y., Azrah, A., Pricilia, G., Sufida, S., Rifsal, D., et al., 2021. Triple-Negative Breast Cancer Clinicopathology: A Single-Center Experience. *Indonesian Journal of Cancer*, **15**: 125–128.
- Hooghe, B., Hulpiau, P., van Roy, F., and De Bleser, P., 2008. ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. *Nucleic Acids Research*, **36**: W128-132.
- Huang, Q., Mei, Z., and Han, X., 2022. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials. *Frontiers in Oncology*, **12**: .
- Hudis, C.A., Barlow, W.E., Costantino, J.P., Gray, R.J., Pritchard, K.I., Chapman, J.-A.W., et al., 2007. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **25**: 2127–2132.
- Iatropoulos, M.J. and Williams, G.M., 1996. Proliferation markers. *Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Fur Toxikologische Pathologie*, **48**: 175–181.
- Ibrahim, T., Farolfi, A., Scarpi, E., Mercatali, L., Medri, L., Ricci, M., et al., 2012. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact. *Oncology*, **84**: 150–157.
- Ismail-Khan, R. and Bui, M.M., 2010. A review of triple-negative breast cancer. *Cancer Control: Journal of the Moffitt Cancer Center*, **17**: 173–176.

- Jacquemier, J.D., Penault-Llorca, F.M., Bertucci, F., Sun, Z.Z., Houvenaeghel, G.F., Geneix, J.A., et al., 1998. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. *The Journal of Pathology*, **184**: 130–135.
- Jonat, W. and Arnold, N., 2011. Is the Ki-67 labelling index ready for clinical use? *Annals of Oncology*, **22**: 500–502.
- Jung, S.Y., Rosenzweig, M., Sereika, S.M., Linkov, F., Brufsky, A., and Weissfeld, J.L., 2012. Factors associated with mortality after breast cancer metastasis. *Cancer causes & control: CCC*, **23**: 103–112.
- Kaplan, H.G. and Malmgren, J.A., 2008. Impact of triple negative phenotype on breast cancer prognosis. *The Breast Journal*, **14**: 456–463.
- Kaplan, H.G., Malmgren, J.A., and Atwood, M.K., 2017. Triple-negative breast cancer in the elderly: Prognosis and treatment. *The Breast Journal*, **23**: 630–637.
- Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J.H., et al., 2011. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Research : BCR*, **13**: R22.
- Kilickap, S., Demirci, U., Karadurmus, N., Dogan, M., Akinci, B., and Sendur, M.A.N., 2018. Endpoints in oncology clinical trials. *Journal of B.U.ON.: official journal of the Balkan Union of Oncology*, **23**: 1–6.

- Kishore, J., Goel, M., and Khanna, P., 2010. Understanding survival analysis: Kaplan-Meier estimate. *International Journal of Ayurveda Research*, **1**: 274.
- Kitamura, M., Nakayama, T., Mukaisho, K.-I., Mori, T., Umeda, T., Moritani, S., et al., 2019. Progression Potential of Ductal Carcinoma in situ Assessed by Genomic Copy Number Profiling. *Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology*, **86**: 92–101.
- Klöppel, G., Perren, A., and Heitz, P.U., 2004. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. *Annals of the New York Academy of Sciences*, **1014**: 13–27.
- Komite Nasional Penanggulangan Kanker, 2015. Panduan Nasional Penanganan Kanker - Kanker Payudara.
- Koo, M.M., von Wagner, C., Abel, G.A., McPhail, S., Rubin, G.P., and Lyratzopoulos, G., 2017. Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis. *Cancer Epidemiology*, **48**: 140–146.
- Kulkarni, A., Kelkar, D.A., Parikh, N., Shashidhara, L.S., Koppiker, C.B., and Kulkarni, M., 2020. Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer. *JCO Global Oncology*, **6**: GO.20.00054.
- Kumar, P. and Aggarwal, R., 2016. An overview of triple-negative breast cancer. *Archives of Gynecology and Obstetrics*, **293**: 247–269.

Lai, E., Persano, M., Dubois, M., Spanu, D., Donisi, C., Pozzari, M., et al., 2022.

Drug-related toxicity in breast cancer patients: a new path towards tailored treatment?—a narrative review. *Precision Cancer Medicine*, **5**: 15–15.

Lebwohl, D., Kay, A., Berg, W., Baladi, J.F., and Zheng, J., 2009. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. *Cancer Journal (Sudbury, Mass.)*, **15**: 386–394.

Lemeshow, S., Hosmer, D.W., Klar, J., and Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*. John Wiley & Sons.

LeVasseur, N., Sun, J., Gondara, L., Diocee, R., Speers, C., Lohrisch, C., et al., 2020. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. *Journal of Cancer Research and Clinical Oncology*, **146**: 529–536.

Li, J., Chen, L., Tan, W., Qi, F., Zhang, Y., Wang, Z., et al., 2022. Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis. *Cancer Biology & Medicine*, **19**: 742–754.

Liedtke, C., Kolberg, H.-C., Kerschke, L., Görlich, D., Bauerfeind, I., Fehm, T., et al., 2018. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). *Clinical & Experimental Metastasis*, **35**: 777–783.

Liedtke, C., Mazouni, C., Hess, K.R., André, F., Tordai, A., Mejia, J.A., et al., 2008. Response to Neoadjuvant Therapy and Long-Term Survival in Patients

With Triple-Negative Breast Cancer. *Journal of Clinical Oncology*, **26**: 1275–1281.

Lin, N.U., Claus, E., Sohl, J., Razzak, A.R., Arnaout, A., and Winer, E.P., 2008.

Sites of Distant Relapse and Clinical Outcomes in Patients with Metastatic Triple-Negative Breast Cancer: High Incidence of Central Nervous System Metastases. *Cancer*, **113**: 2638–2645.

Lin, N.U., Vanderplas, A., Hughes, M.E., Theriault, R.L., Edge, S.B., Wong, Y.-

N., et al., 2012. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. *Cancer*, **118**: 5463–5472.

Loibl, S. and Gianni, L., 2017. HER2-positive breast cancer. *Lancet (London, England)*, **389**: 2415–2429.

Loibl, S., Sikov, W., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., et al., 2021. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after  $\geq 4$  years of follow-up: BrighTNess, a randomized phase III trial. *Annals of Oncology*, **32**: S408.

Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanisławek, A., 2021. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*, **13**: 4287.

- Mahvi, D.A., Liu, R., Grinstaff, M.W., Colson, Y.L., and Raut, C.P., 2018. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. *CA: a cancer journal for clinicians*, **68**: 488–505.
- McKee, A.E., Farrell, A.T., Pazdur, R., and Woodcock, J., 2010. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. *The Oncologist*, **15 Suppl 1**: 13–18.
- Mielke, S., Sparreboom, A., Steinberg, S.M., Gelderblom, H., Unger, C., Behringer, D., et al., 2005. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, **11**: 4843–4850.
- Morante, Z., De la Cruz Ku, G.A., Enriquez, D., Saavedra, A., Luján, M., Luque, R., et al., 2018. Post-recurrence survival in triple negative breast cancer. *Journal of Clinical Oncology*, **36**: e13120–e13120.
- Morris, G.J., Naidu, S., Topham, A.K., Guiles, F., Xu, Y., McCue, P., et al., 2007. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and end results database. *Cancer*, **110**: 876–884.
- Narod, S.A., 2018. Personalised medicine and population health: breast and ovarian cancer. *Human Genetics*, **137**: 769–778.
- National Cancer Institute, 2017. Common Terminology Criteria for Adverse Events (CTCAE).

National Comprehensive Cancer Network, 2023. Breast Cancer (5.2023).

Niwińska, A., Murawska, M., and Pogoda, K., 2010. Breast cancer brain metastases:

differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **21**: 942–948.

Notoadmodjo, S., 2005. *Metode Penelitian Kesehatan*. Rineka Cipta, Jakarta.

O'Reilly, D., Sendi, M.A., and Kelly, C.M., 2021. Overview of recent advances in metastatic triple negative breast cancer. *World Journal of Clinical Oncology*, **12**: 164–182.

Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L.E., Gómez-Valles, F.O., and Ramírez-Valdespino, C.A., 2022. Subtypes of Breast Cancer, in: Mayrovitz, H.N. (Editor), *Breast Cancer*. Exon Publications, Brisbane (AU).

O'Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., et al., 2002. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **20**: 2812–2823.

Oun, R., Moussa, Y.E., and Wheate, N.J., 2018. The side effects of platinum-based chemotherapy drugs: a review for chemists. *Dalton Transactions*, **47**: 6645–6653.

- Pennisi, A., Kieber-Emmons, T., Makhoul, I., and Hutchins, L., 2016. Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. *Breast Cancer: Basic and Clinical Research*, **10**: 103–106.
- Pignata, S., De Placido, S., Biamonte, R., Scambia, G., Di Vagno, G., Colucci, G., et al., 2006. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. *BMC Cancer*, **6**: 5.
- Poggio, F., Tagliamento, M., Ceppi, M., Bruzzone, M., Conte, B., Fregatti, P., et al., 2022. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate. *Annals of Oncology*, **33**: 347–349.
- Pogoda, K., Niwińska, A., Murawska, M., and Pieńkowski, T., 2013. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. *Medical Oncology*, **30**: 388.
- Prinja, S., Gupta, N., and Verma, R., 2010. Censoring in clinical trials: review of survival analysis techniques. *Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive & Social Medicine*, **35**: 217–221.
- Ren, Y.-X., Hao, S., Jin, X., Ye, F.-G., Gong, Y., Jiang, Y.-Z., et al., 2019. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. *The Breast*, **43**: 97–104.



- Sahoo, S. and Lester, S.C., 2009. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. *Archives of Pathology & Laboratory Medicine*, **133**: 633–642.
- Sargent, R.E., Vazquez, E., Kang, I., Lu, J., Manchandia, T., Sheth, P., et al., 2022. Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center. *The American Journal of Surgery*, **223**: 539–542.
- Scheithauer, W., Kornek, G.V., Raderer, M., Schüll, B., Schmid, K., Kovats, E., et al., 2003. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **21**: 1307–1312.
- Schoenfeld, D.A., 1983. Sample-Size Formula for the Proportional-Hazards Regression Model. *Biometrics*, **39**: 499–503.
- Schwartz, M.A., 2014. High-dose methotrexate for metastatic breast cancer to the central nervous system: A single-institution review of 46 patients. *Journal of Clinical Oncology*, **32**: 1079–1079.
- Scott, L.C., Mobley, L.R., Kuo, T.-M., and Il'yasova, D., 2019. Update on Triple Negative Breast Cancer Disparities for the United States – A Population Based Study from the United States Cancer Statistics database, 2010-2014. *Cancer*, **125**: 3412–3417.

- Scripture, C.D., Figg, W.D., and Sparreboom, A., 2006. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. *Current Neuropharmacology*, **4**: 165–172.
- Seidman, A., Hudis, C., Pierri, M.K., Shak, S., Paton, V., Ashby, M., et al., 2002. Cardiac dysfunction in the trastuzumab clinical trials experience. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **20**: 1215–1221.
- Sharma, P., López-Tarruella, S., García-Saenz, J.A., Khan, Q.J., Gómez, H.L., Prat, A., et al., 2018. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. *Clinical cancer research : an official journal of the American Association for Cancer Research*, **24**: 5820–5829.
- Shirendeb, U., Hishikawa, Y., Moriyama, S., Win, N., Thu, M.M.M., Mar, K.S., et al., 2009. Human Papillomavirus Infection and Its Possible Correlation with p63 Expression in Cervical Cancer in Japan, Mongolia, and Myanmar. *Acta Histochemica Et Cytochemica*, **42**: 181–190.
- Sikov, W.M., Berry, D.A., Perou, C.M., Singh, B., Cirrincione, C.T., Tolaney, S.M., et al., 2015. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). *Journal of Clinical Oncology*, **33**: 13–21.

Sivina, E., Blumberga, L., Purkalne, G., and Irmejs, A., 2023. Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience. *Hereditary Cancer in Clinical Practice*, **21**: 4.

Sjöström, M., Lundstedt, D., Hartman, L., Holmberg, E., Killander, F., Kovács, A., et al., 2017. Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **35**: 3222–3229.

Sobočan, M., Turk, M., Čater, P., Sikošek, N.Č., Crnobrnja, B., Takač, I., et al., 2019. Clinical features and their effect on outcomes of patients with triple negative breast cancer with or without lymph node involvement. *The Journal of International Medical Research*, **48**: 0300060519887259.

Sujarweni, V.W., 2020. *Metodologi Penelitian*. Pustaka Baru Press.

Tzikas, A.-K., Nemes, S., and Linderholm, B.K., 2020. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. *Breast Cancer Research and Treatment*, **182**: 643–654.

U.S. Department of Health and Human Services (last), Food and Drug Administration, Oncology Center of Excellence, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER), 2020. *Pathological Complete Response in Neoadjuvant*

*Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry.* U.S. Food and Drug Administration, Silver Spring, MD.

von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S.D., Eidtmann, H., Fasching, P.A., et al., 2012. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **30**: 1796–1804.

Wahba, H.A. and El-Hadaad, H.A., 2015. Current approaches in treatment of triple-negative breast cancer. *Cancer Biology & Medicine*, **12**: 106–116.

Wang, S., Yang, H., Tong, F., Zhang, J., Yang, D., Liu, H., et al., 2009. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. *Gan to Kagaku Ryoho. Cancer & Chemotherapy*, **36**: 255–258.

Wang, X.-X., Jiang, Y.-Z., Li, J.-J., Song, C.-G., and Shao, Z.-M., 2016. Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. *Oncotarget*, **7**: 46636–46645.

Wickberg, Å., Magnuson, A., Holmberg, L., Adami, H.-O., and Liljegren, G., 2018. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy. *Breast (Edinburgh, Scotland)*, **42**: 54–60.

Wilson, M.K., Karakasis, K., and Oza, A.M., 2015. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. *The Lancet. Oncology*, **16**: e32-42.

World Health Organization International Agency for Research on Cancer (IARC), 2021. GLOBOCAN 2020: Indonesia Fact Sheet.

Wu, Q., Siddharth, S., and Sharma, D., 2021. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. *Cancers*, **13**: 3697.

Xia, Y., Cui, L., and Yang, B., 2014. A note on breast cancer trials with pCR-based accelerated approval. *Journal of Biopharmaceutical Statistics*, **24**: 1102–1114.

Xiu, M., Zhang, P., Li, Qing, Yuan, P., Wang, J., Luo, Y., et al., 2022. Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice. *Frontiers in Oncology*, **12**: 867583.

Yang, V., Gouveia, M.J., Santos, J., Kokschi, B., Amorim, I., Gärtner, F., et al., 2020. Breast cancer: insights in disease and influence of drug methotrexate. *RSC Medicinal Chemistry*, **11**: 646–664.

Yin, J., Zhu, C., Wang, G., and Gu, J., 2022. Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses. *International Journal of General Medicine*, **15**: 5901–5914.

Yu, K.-D., Ye, F.-G., He, M., Fan, L., Ma, D., Mo, M., et al., 2020. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-

Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **6**: 1390–1396.

Zeuli, M., Nardoni, C., Pino, M.S., Gamucci, T., Gabriele, A., Ferraresi, V., et al., 2003. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **14**: 1378–1382.

Zhang, H., Wang, Z., Liu, W., Wang, P., and Zhang, X., 2023. Breast-Conserving Surgery in Triple-Negative Breast Cancer: A Retrospective Cohort Study. *Evidence-Based Complementary and Alternative Medicine*, **2023**: e5431563.

Zhang, J., Wu, Q., Yin, W., Yang, L., Xiao, B., Wang, J., et al., 2023. Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. *BMC cancer*, **23**: 431.

Zhang, L., Fang, C., Xu, X., Li, A., Cai, Q., and Long, X., 2015. Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis. *BioMed Research International*, **2015**: 1–12.

Zhu, H. and Doğan, B.E., 2021. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians. *European Journal of Breast Health*, **17**: 234–238.

Zhu, X., Chen, L., Huang, B., Wang, Y., Ji, L., Wu, J., et al., 2020. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. *Scientific Reports*, **10**: 225.

Ziepert, M., Schmits, R., Trümper, L., Pfreundschuh, M., and Loeffler, M., 2008.

Prognostic factors for hematotoxicity of chemotherapy in aggressive non-

Hodgkin's lymphoma. *Annals of Oncology*, **19**: 752–762.

Zonneveld, I.M., Bakker, W.K., Dijkstra, P.F., Bos, J.D., van Soesbergen, R.M.,

and Dinant, H.J., 1996. Methotrexate osteopathy in long-term, low-dose

methotrexate treatment for psoriasis and rheumatoid arthritis. *Archives of*

*Dermatology*, **132**: 184–187.